Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 11/20 | 0.72 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.72 |
| ▸ | USP5 | P45974 | 1/20 | 0.72 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21594732 | 1.00 | USP9X (0.72) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864194 | 0.89 | USP9X (0.75) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864195 | 0.89 | USP9X (0.75) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL10124900 | 0.89 | USP9X (0.78) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL859666 | 0.87 | USP9X (0.81) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL859667 | 0.87 | USP9X (0.81) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864393 | 0.87 | USP9X (0.81) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863759 | 0.85 | USP9X (0.72) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863758 | 0.85 | USP9X (0.72) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863498 | 0.85 | USP9X (0.71) | USP9XUCHL1USP5STAT3USP24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3807263-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | Amphista Therapeutics Ltd (GB) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238816-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238886-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING USP14 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UCHL5, UCHL3, UCHL1 | USP9X 99/4885UCHL1 3/4885USP5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.